Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497221 | 0.85 | ALDH1A1 (0.46) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1284863 | 0.83 | NPSR1 (0.39) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1985647 | 0.83 | NPSR1 (0.39) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12737271 | 0.83 | NPSR1 (0.42) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5531263 | 0.83 | NPSR1 (0.42) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28450802 | 0.83 | NPSR1 (0.42) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL26418631 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHREGLN1HCAR2 | |
| SCHEMBL5144387 | 0.80 | NPSR1 (0.43) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5144385 | 0.80 | NPSR1 (0.43) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7600152 | 0.79 | NPSR1 (0.46) | NPSR1GLO1SOAT1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20180133223-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170304279-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9657032-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160185796-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2016-06-30 | — | — | US | disclosed |
| US-9249156-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140243330-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8710219-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20130090335-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS,INC. | 2013-04-11 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| EP-2157095-A2 | Synthesis of beta-L-2-Deoxy nucleosides | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885SOAT1 2290/4885 |
| US-20130090335-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | HDAC1, PI4KA, PDPK1 | NPSR1 4579/4885GLO1 4378/4885SOAT1 1395/4885 |
| US-20170304279-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | HDAC1, PI4KA, PDPK1 | NPSR1 4579/4885GLO1 4378/4885SOAT1 1395/4885 |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | HDAC5, HDAC2, HDAC8 | NPSR1 3164/4885GLO1 4705/4885SOAT1 1408/4885 |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885SOAT1 2290/4885 |
| US-20140243330-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | HDAC1, PI4KA, PDPK1 | NPSR1 4579/4885GLO1 4378/4885SOAT1 1395/4885 |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | HDAC1, PI4KA, PDPK1 | NPSR1 4579/4885GLO1 4378/4885SOAT1 1395/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885SOAT1 2290/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885SOAT1 2290/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4690/4885GLO1 4495/4885SOAT1 2418/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | NPSR1 4175/4885GLO1 2837/4885SOAT1 2531/4885 |
| US-20180133223-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | BAK1, BCLAF1, BCL2 | NPSR1 4663/4885GLO1 4404/4885SOAT1 871/4885 |
| US-20160185796-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | HDAC1, PI4KA, PI4K2B | NPSR1 4600/4885GLO1 4355/4885SOAT1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.